Initial experience with the cook formula balloon expandable stent in congenital heart disease by Quandt, Daniel et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2015
Initial experience with the cook formula balloon expandable stent in
congenital heart disease
Quandt, Daniel; Ramchandani, Bharat; Bhole, Vinay; Penford, Gemma; Mehta, Chetan; Dhillon, Rami;
Stumper, Oliver
Abstract: INTRODUCTION: Balloon expandable stents are an integral part in the catheter treatment
of congenital heart disease. In the growing child, stents require dilatation to greater diameters over time.
The Cook Formula stent is a recent 316 stainless steel open-cell design licensed for peripheral vascular
work. METHODS: Following extensive ex vivo studies, 112 stents were implanted in 97 children [median
age 3.9 (0.01-17.6) years; median weight 13.7 (2.4-62.8) kg] over a 27-month (Oct 2011-Dec 2013) period.
RESULTS: Bench testing revealed that there was no stent shortening for dilatation to nominal diameter
and beyond. The 5 mm stents could be dilated up to 10 mm, and the 10 mm stents to 20 mm. Stents were
implanted through 4-7F sheaths or guide catheters over appropriate wires. Stent tracking and delivery
was excellent. Twenty-three stents were implanted in the right ventricular outflow tract in Fallot-type
lesions, 53 for branch pulmonary artery stenosis (22 post cavopulmonary shunt/Fontan), 14 conduit
stenosis, 13 Fontan fenestrations, 3 PDA in hybrid stage I Norwood, 5 in coarctation, and 1 for SVC
obstruction. Sixty-one stents (54%) were overdilated. There were no stent fractures. Radial strength
was very good, whereas stent conformability was limited. CONCLUSIONS: The Cook Formula stent is a
premounted balloon-expandable stent that can be significantly overdilated with virtually no shortening
allowing for precise placement and minimal protrusion into adjacent vessels. The Formula stent is a very
versatile addition to the range of stents for use in the catheter treatment of complex congenital heart
disease in children. © 2014 Wiley Periodicals, Inc.
DOI: 10.1002/ccd.25543
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-120050
Published Version
 
 
Originally published at:
Quandt, Daniel; Ramchandani, Bharat; Bhole, Vinay; Penford, Gemma; Mehta, Chetan; Dhillon, Rami;
Stumper, Oliver (2015). Initial experience with the cook formula balloon expandable stent in congenital
heart disease. Catheterization and Cardiovascular Interventions, 85(2):259-266. DOI: 10.1002/ccd.25543
Initial Experience with the Cook Formula Balloon
Expandable Stent in Congenital Heart Disease
Daniel Quandt, MD, Bharat Ramchandani, MD, MRCP, Vinay Bhole, MD, MRCPCH, Gemma
Penford, MRCP, Chetan Mehta, MD, MRCP, Rami Dhillon, MRCP, and Oliver Stumper*, MD, PhD
Introduction: Balloon expandable stents are an integral part in the catheter treatment
of congenital heart disease. In the growing child, stents require dilatation to greater
diameters over time. The Cook Formula stent is a recent 316 stainless steel open-cell
design licensed for peripheral vascular work. Methods: Following extensive ex vivo
studies, 112 stents were implanted in 97 children [median age 3.9 (0.01–17.6) years;
median weight 13.7 (2.4–62.8) kg] over a 27-month (Oct 2011–Dec 2013) period.
Results: Bench testing revealed that there was no stent shortening for dilatation to
nominal diameter and beyond. The 5 mm stents could be dilated up to 10 mm, and the
10 mm stents to 20 mm. Stents were implanted through 4–7F sheaths or guide cathe-
ters over appropriate wires. Stent tracking and delivery was excellent. Twenty-three
stents were implanted in the right ventricular outflow tract in Fallot-type lesions, 53 for
branch pulmonary artery stenosis (22 post cavopulmonary shunt/Fontan), 14 conduit
stenosis, 13 Fontan fenestrations, 3 PDA in hybrid stage I Norwood, 5 in coarctation,
and 1 for SVC obstruction. Sixty-one stents (54%) were overdilated. There were no
stent fractures. Radial strength was very good, whereas stent conformability was lim-
ited. Conclusions: The Cook Formula stent is a premounted balloon-expandable stent
that can be significantly overdilated with virtually no shortening allowing for precise
placement and minimal protrusion into adjacent vessels. The Formula stent is a very
versatile addition to the range of stents for use in the catheter treatment of complex
congenital heart disease in children. VC 2014 Wiley Periodicals, Inc.
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INTRODUCTION
Stents are increasingly being used in the treatment
of congenital heart disease [1–7]. The preference is for
balloon expandable stainless-steel stents, as they pro-
vide sufficient radial strength and allow for future fur-
ther dilatations, to accommodate for somatic growth
[4,8]. There are a wide variety of stents available [9],
yet only few have been licensed for use in cardiac
indications—thus, stents in the treatment of congenital
heart disease are mostly used off-label [10].
The ideal stent for use in congenital heart disease
patients should be premounted [11], deliverable
through small sheaths, be flexible, redilatable to 15–
18 mm maximum size, should have minimal shorten-
ing, and have good radial strength. Self-expanding
stents cannot be over-dilated and thus do not fit the
bill [12]. Coronary balloon-expandable stents are very
flexible and can be introduced through 4F sheaths or
6F guide catheters, but cannot be expanded beyond 6
or 7 mm [13].
Thus, most pediatric cardiologists have looked at
using stents initially designed for biliary or renal work.
Such stents have nominal diameters of 5–10(12) mm
and potentially can be dilated further [14–17]. Ex vivo
bench testing, in particular to look at shortening char-
acteristics of these stents during over dilation has been
pioneered by Ing and Stern [2,16].
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The Cook Formula stent family is a relatively recent
hybrid cell design licensed for biliary, renal and pe-
ripheral vascular work. This report summarizes our ex-
perience with this stent in the treatment of children
with a wide variety of congenital heart disease over a
27-month period between October 2011 and December
2013.
METHODS AND PATIENTS
Until mid 2011 the balloon expandable stent most
commonly used in our institution for the treatment of
pulmonary artery stenoses was the JoStent (Abbott
Vascular, Abbott Park, IL). When production ceased at
the end of 2010 we needed a replacement. Various
designs and manufacturers were considered. Following
local bench testing, the clinical consensus was to use
the Cook Formula stent family in our pediatric cardiac
practice.
Bench Testing
Bench testing was carried out with sample stent
designs provided by various companies. Stents were
inflated and expanded to their nominal diameter rec-
ommended by each stent manufacturer. Stents were
then serially overdilated using a series of noncompliant
balloons in sequential size increments of 2 mm. Short-
ening characteristics, stent integrity (e.g., strut design,
fractures, etc.), as well as stent diameter and stent
length were measured at each sequential stage of over-
dilation. Balloons used for overdilation (12–24 mm)
were the Cordis PowerflexVR , Cordis OPTAVR (Johnson
and Johnson, Cordis Corporation, Miami Lakes, FL)
and the Bard ATLASVR PTA Dilatation Catheter (Bard
Peripheral Vascular, Tempe, AZ). It was important to
use short balloons to prevent “dog boning” of the
stents.
Patients
All patients who underwent Cook formula stent im-
plantation at our institution were included in this
review. Between Oct 2011 and Dec 2013 112 Cook
Formula stents were implanted in 97 patients with pre-
or post-operative congenital heart disease. Median age
at implantation was 3.9 years (range, 2 days–17.6
years) and median weight 13.7 (range, 2.4–62.8) kilo-
gram. Fifty-two (54%) patients were male.
Procedures
All catheter procedures were carried out under gen-
eral anaesthesia with endotracheal intubation. Intrave-
nous Heparin (50iU/kg) was administered in all.
Complete hemodynamic and angiographic studies were
carried out. Stents were implanted by Consultants or
senior fellows in interventional cardiology. Routine an-
tibiotic prophylaxis for implants was administered.
Stents were delivered through a 4 or 5 French Cook
Flexor sheath or a 6 French Coronary guide catheter
over a 0.014” wire, or over a 0.035” wire via a 7 F
Mullins sheath. Since March 2013 we have been
increasingly using the Cook 418 Formula stents, which
are over the wire designs up to 8 mm nominal diame-
ter. These can be delivered through 5 and 6F sheaths
and the 8 mm stent can be overdilated to 17 mm.
Repeat angiography and hemodynamic assessment,
together with cardiac ultrasound evaluation was carried
out before sheath and wires were withdrawn and man-
ual hemostasis was employed. All patients were com-
menced on Aspirin medication 3–5 mg/kg post
procedure.
Indications
Thirty-eight patients had a univentricular and 59
patients a bi-ventricular circulation. The stents were
placed for short (n¼ 24), medium (n¼ 24), or long-
term indications (n¼ 64), depending on the underlying
lesion and the anticipated benefit. Twenty-two patients
underwent stenting of the right ventricular outflow tract
in the context of a Fallot-type lesions or stenting of the
ductus arteriosus (n¼ 3) in the setting of a hybrid pro-
cedure for Norwood stage I palliation (short-term).
Twenty patients underwent stenting of a cardiac con-
duit, residual outflow obstruction or Fontan fenestra-
tion (medium-term and long-term). Fifty-two patients
underwent stenting for (re-)coarctation, venous obstruc-
tions, or pulmonary artery stenosis in uni-or bi-ventric-
ular circulations (long term). In 11 patients two stents
were implanted during the same procedure (Fig. 3).
Outcome measures (e.g., improvement of oxygen
saturations in RVOT stenting, increase of stented ves-
sel diameter in pulmonary artery stenting, drop in oxy-
gen saturation in Fontan fenestration stenting) were
assessed and compared pre- and postintervention. Sta-
tistical analysis was performed using student’s t-tests.
Follow-Up
All patients underwent clinical assessment and echo-
cardiography on the day post procedure. Following
hospital discharge all patients underwent detailed clini-
cal follow-up including serial cardiac ultrasound stud-
ies, with the first review 2–6 weeks after the procedure
and then based on clinical and echocardiographic find-
ings. Repeat chest x-rays were only performed prior to
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elective cardiac surgical intervention or incidental chest
infections. Repeat cardiac catheterization or CT (com-
puted tomography)/CMR (cardiac magnet resonance)
imaging was only carried out on clinical grounds.
Ethical Approval
Stenting procedures in the treatment of congenital
heart disease at our institution have been approved and
used since 1992 with a variety of equipment. Individ-
ual stent designs are locally approved by the Drugs
and Therapeutics committee. Ongoing analysis of the
results of the use of stents in congenital heart disease
is deemed mandatory as part of local clinical gover-
nance arrangements and thus the need for specific ethi-
cal approval for this study was waived. All patients
and their parents gave their consent for on-going local
and national clinical audit of the results of cardiac
catheter interventions.
RESULTS
Bench testing was carried out using sample stents
provided by the different companies (examples of
bench testing are illustrated in Fig. 1). The Cook For-
mula stent was tested further due to the nonshortening
characteristics and the ability to overdilate the stents
significantly without a dramatic loss of radial strength.
Sample stents were dilated to nominal diameter and
the length was measured. Further bench dilatation was
carried out using appropriate balloons, and achieved di-
ameter and lengths were assessed (Fig. 2). The Cook
Formula 414, 5, and 6 mm diameter stents were over-
dilated to a maximum of 11–12 mm diameter, the
Fig. 1. A: Bench testing of a Cook formulaVR 418, 8 3 20 mm
stent (single black arrow), a Bard ValeoVR stent (*) 10 3 36 mm
and Abbott VascularVR Jomed stent large (6–12 mm)—38 mm
(double black arrow). Note the different stent and strut archi-
tecture. B: All three different stent types overdilated to 15 mm
diameter. C: Illustrating no shorting of the Cook formula stent
with integrity of its open/hybrid cell design. Note the different
cell design and its behaviour during overdilation, especially
for the Bard ValeoVR stent. D–F: Illustrates significant shorten-
ing characteristics for the Abbott VascularVR Jomed large (6–
12 mm)238 mm during sequential dilation to nominal diameter
(D), and further overdilation (E and F). [Color figure can be
viewed in the online issue, which is available at wileyonlineli-
brary.com.]
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Cook Formula 418, 8 mm diameter up to 16 mm and
the Cook Formula 535, 10 mm diameter up to maximal
20 mm. It was important to use short balloon lengths
to achieve maximal diameter—ideally the same length
or shorter than the actual stent [16].
A total of 112 Cook Formula stents were implanted
in 97 patients over the 27 months observation period
(Fig. 3). Thirteen patients underwent implantation of
two stents during the same procedure and two addi-
tional patients had a reintervention using a further
Cook formula stent.
Median procedure time was 80 (18–222) min and
median screening time was 23 (5–76) minutes. There
were no procedural deaths. There were two balloon
ruptures (both in patients with previously placed coro-
nary stents) with fracture and embolization of the distal
balloon tip in one, which was successfully retrieved.
There were two stent embolizations, one in a patient
undergoing RVOT stenting, one in a patient under-
going left pulmonary artery stenting—both stents were
successfully retrieved using a large bore long sheath
and a gooseneck snare. One of these patients had a fur-
ther stent placed successfully positioned in the RVOT;
in the other patient the procedure was abandoned.
Nineteen patients underwent stenting of the native
right ventricular outflow tract for Fallot type lesions
(additional three patients underwent stenting of the
right ventricular outflow tract after previous RVOT
stenting with a different stent type), at a median age of
4 months (2 days–11.9 years) and a median weight of
5.3 (2.9–24) kilogram. Stents used had a median diam-
eter of 6(5–10) mm and a median length of 16 (12–20)
mm. Systemic arterial saturations increased from 78
(66–93)% to 93 (89–98)% [P< 0.001].
Fig. 2. Bench testing and overdilation of a Cook formula 414,
6 3 16 mm stent (top row) and a Cook formula 535, 10 3
20 mm stent (bottom row). Ia and IIa) Dilation to nominal di-
ameter, Ib and IIb) Subsequent serial overdilation of the stents
during bench testing, Ic and IIc) Stent length after overdilation
to max. 12 mm (top row) and max. 18 mm (bottom row) show-
ing no stent shortening, Id and IId) Illustrates stent diameter
overdilated to max. 12 mm for the Cook formula 414, 6 3
16 mm stent and max. 18 mm for the Cook formula 535, 10 3
20 mm stent with integrity of stent struts and stent architec-
ture.
Fig. 3. Indications (x-axis) for 112 Cook Formula stents and
number of stents (y-axis) implanted at different sites (x-axis).
[RVOT, Right Ventricular Outflow Tract].
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Forty-seven patients underwent stenting of branch
pulmonary artery stenosis (bilateral in 4). Pre proce-
dural minimal pulmonary artery diameter was a median
of 4.75 (1.0–8.0) mm and increased post stenting to 10
(5.0–15.0) mm [P< 0.001].
Thirteen stents were used in 12 patients for stenting
of a Fontan fenestration in the early postoperative pe-
riod for low cardiac output, prolonged pleural effu-
sions, or protein losing enteropathy. The most
commonly used stent was a 5  16 mm (five patients)
or 6  12 mm (three patients) Formula stent which
was subsequently flared to 10 mm achieving a diabolo
configuration. Saturations decreased from a median 95
(85–100)% to 88 (83–92)% [P< 0.01].
Thirteen patients underwent stenting of a right ven-
tricular to pulmonary artery conduit. Eleven of these
had a biventricular circulation and pressure gradients
were reduced from a median of 48 (32–76) mm Hg to
15 (8–25) mm Hg [P< 0.001].
Nine stents were implanted for miscellaneous lesions
such as (re-)coarctation (five patients, two with univen-
tricular circulation), obstruction of the superior vena
cava (n¼ 1), or for maintaining ductal patency in a
stage I Norwood hybrid procedure (n¼ 3). One patient
with coarctation stenting had Alagille’s syndrome and
one patient had Williams-Beurren syndrome, whereas
one stent was implanted in a patient with recoarctation
and previous stenting of the CoA with a Jomed stent.
Sixty-one stents (54%) placed were primarily overdi-
lated by a median of 2 (1–6) mm resulting in a median
increase of 25 (14–100)% above nominal diameter (Fig.
4). A total of 10 stents (9%) were further dilated during
the follow-up period by a median of 2(1–4) mm.
All patients underwent serial clinical assessments
and echocardiography during follow-up. Length of
clinical follow-up time was median 220 days (range,
12–762 days) for all stents. On clinical grounds there
was no suspicion of stent fractures or stent occlusions
over the observation period. Further imaging (including
chest x-rays or CT angio, CMR) were only performed
based on other clinical indications, not to check stent
conformation alone. Overall 91/112 stents (81%) were
visualized with other imaging modalities during
follow-up. Eighteen stents (16%) were visualized dur-
ing repeat cardiac catheterization, 62 stents (55%) on
chest x-rays (median 61 days post procedure) and a
further 16 (14%) were visualized on CT angio/MRI
(see also Table I). There were no stent fractures or
stent occlusions noted on further imaging during the
follow-up period.
Fig. 4. Stenting of right pulmonary artery stenosis in a 3-year-old (13 kg) patient after com-
plete repair of a common arterial trunk with a 15 m aortic homograft (RV/PA conduit). A: RPA
origin stenosis, B: initial stenting with Cook formula 414, 7 3 20 mm stent. C: Overdilation of
stent with 10 3 20 mm balloon with no stent shortening, D: Final result.
Cook Formula Balloon Expandable Stent 263
Catheterization and Cardiovascular Interventions DOI 10.1002/ccd.
Published on behalf of The Society for Cardiovascular Angiography and Interventions (SCAI).
The observation period for all stents was shortest for
the RVOT and PDA stents, as these stents were
implanted for short-term palliation only. Two RVOT
stents were surgically removed after 12 and 23 days
during complete repair of Fallot. Overall 25/112 stents
(22%) were removed at the time of further surgery.
DISCUSSION
After the initial work by Mullins and colleagues
[5,7] stents have become an integral part in the treat-
ment of congenital heart disease. In growing patients it
is important that stents can be further dilated over
time—certainly in cases where no further intervention
is planned. Self-expanding stents are therefore obsolete
in most cases or indications. Stainless steel stents offer
sufficient radial strength for most congenital applica-
tions. Premounted stents are convenient to use and
reduce procedure time and normally can be delivered
through smaller sheaths [11].
Stents with a closed cell design shorten with further
dilatation. Over the years many operators and centers
got accustomed to this and learned to accommodate
for this stent behavior during initial stent selection
and placement. During initial or subsequent over-
dilatation there was marked shortening of the stent
ranging from 18 to 50% [13,18,19]. Interestingly, no
reports are available to detail the effect such shorten-
ing has on the neo-intima covering the stent after im-
plantation. The latest design in stents is the open cell
or hybrid architecture, which holds promise of signifi-
cant overdilatation without marked shortening. This
should limit the intimal damage during later progres-
sive dilatation.
The Cook Formula stent is one of the new genera-
tion hybrid open-cell design stainless steel stents.
These stents are currently only licensed for noncardiac
interventions. In Europe there has been a long estab-
lished practice to consider the use of devices on an
off-label basis for cardiac interventions under local
clinical governance scrutiny, given that these devices
are considered safe for use in other parts of the body
or the circulation and are approved for human use by
the international legislating bodies. For many years,
we, and many other institutions, have used stents
approved for biliary and renal interventions in cardiac
applications with good effect.
Nonetheless, the quest for the ideal stent for the
treatment of cardiovascular lesions in the growing child
is still a matter of clinical urgency.
The median age and weight of patients in our series
is relatively low compared with many published series
of stents in congenital heart disease. The ability to
deliver the stent through sheath sizes between 4 and 7FTA
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is attractive, especially in younger children and infants.
The Cook Formula stent is a premounted system,
which comes as a monorail design (414) or as an over-
the wire design (418 and 535) [20]. This saves valua-
ble time and reduces complications in complex proce-
dures. Twenty-two patients in our cohort (23%)
underwent stenting of the RVOT in the setting of Te-
tralogy of Fallot type lesions [21]. These infants are of-
ten fragile and unstable during the procedure and
hence a smooth and rapid stent deployment is neces-
sary. A premounted stent saves time and minimizes the
risk of stent dislodgement during delivery.
The full range of Cook Formula stents were used for
different indications and in the settings of single or bi-
ventricular circulations. This series documents that this
is a versatile stent family, which can be used for indi-
cations ranging from ductal stenting in a neonate to co-
arctation stenting in a teenager. The immediate results
and complication rate are comparable with previous
published series in the literature using different stent
designs in patients with congenital heart disease
[16,17].
The ex vivo testing showed that the Cook formula
stent is remarkably strong and shortens only minimally
even with overdilatation up to 100% of its nominal di-
ameter. In comparison, closed cell design stents can
shorten from 18 to 50% depending on the degree of
overdilatation [22]. The shortening in open cell design
is less but with this family of stents we found virtually
no shortening even with over dilatation up to 100%.
This is a very important feature for any stent implanta-
tion, but especially in small infants where margin for
error is small. The radial strength of this stent is excel-
lent and we have not seen any stent fractures at nomi-
nal stent diameter or beyond. During bench testing we
were able to crack a 10 mm stent with a 20 mm
balloon at 14þ atmosphere pressure—again without
shortening.
It is important to choose an initial size that allows for
future dilatation to a size likely to be required in the me-
dium to long term. In lesions where dilatation beyond
16 mm is required in future, one has to be cautious in
choosing these stents below 7 mm initial diameter.
LIMITATIONS
A significant proportion of our patients had stents
implantation for short to midterm indications. These
stents were removed at the time of subsequent planned
surgery. We did not obtain routine serial follow-up
chest x-rays/fluoroscopy to look for stent fractures, but
81% of the stents were seen on further imaging other
than echocardiography and no issues were encoun-
tered.
CONCLUSIONS
The presented case series indicates that the Cook
Formula stent family is a valuable addition to the stent-
ing of common congenital cardiac lesions. Appropriate
licensing for this indication would allow for greater
use of this stent design for congenital cardiac
indications.
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